L
Longboard Pharmaceuticals
Biotech & Life Sciences · San Diego, United States · Founded 2020 · IPO 2021
A clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases MoreLess
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to creating transformative medicines for neurological diseases, with a particular focus on rare conditions. The company leverages over 20 years of research in G protein-coupled receptors (GPCRs) to develop next-generation treatments. Longboard's pipeline includes innovative compounds like bexicaserin, aimed at treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs), a group of severe epilepsies characterized by drug-resistant seizures and significant developmental delays. The company operates in the biopharmaceutical market, targeting healthcare providers and patients affected by neurological and rare diseases. Longboard's business model involves advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and future product sales.
Keywords: GPCR research, neurological diseases, rare diseases, clinical-stage, biopharmaceutical, transformative medicines, DEEs, seizures, drug-resistant, developmental delays.
Company overview
Longboard Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2020
- Headquarters
- San Diego, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 29.1
Valuation & funding
Longboard Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2024 | $2.6B | $2.6B | Lundbeck | ↗ |
| POST IPO EQUITYOther financing | Jan 2024 | $242M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Feb 2023 | $23M | — | Undisclosed | ↗ |
| IPOOther financing | Mar 2021 | $80M | $80M | Undisclosed | — |
| SEEDOther financing | Oct 2020 | $56M | $224M | Cormorant Asset Management · Highside Capital Management · Farallon Capital Management · Arena Pharmaceuticals | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$57M | — |
| 2025 | $0 | — | −$57M | — |
| 2024 | $0 | — | −$57M | — |
| 2023 | $0 | — | −$57M | — |
| 2022 | $0 | — | −$45M | — |
| 2021 | $0 | — | −$28M | — |
| 2020 | $0 | — | −$14M | — |
Growth signals
Longboard Pharmaceuticals website traffic
Latest recorded traffic for Longboard Pharmaceuticals is 1.2K monthly website visits, up 224.3% over the last three months. Longboard Pharmaceuticals's team declined 72.4% over the past year.
Comparisons
Longboard Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Longboard Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Longboard Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Longboard Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Longboard Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Longboard Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Longboard Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Longboard Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.